| ID | 1194 |
| Name of the vaccine | WRSs2 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | 18 to 49 years |
| Description of the vaccine | Shigella Sonnei vaccine. |
| Name of the manufacturer | National Institute of Allergy and Infectious Diseases (NIAID) |
| Name of the manufacturing country | United States |
| Year of manufacture | 2023 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | One or two doses. |
| Mechanism of action | Serum anti-LPS, anti-Invaplex IgG and IgA. |
| Route of administration | Oral |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Diarrhoea, fever, headache, cramps, vomiting, myalgia and arthralgia. |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | 30037478 |
| Clinical trial number | NCT04242264 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|